Exela Pharma Sciences, LLC v. Lee, No. 13-1206 (Fed. Cir. 2015)
Annotate this CaseExela petitioned the Patent and Trademark Office to “reconsider and withdraw” its revival of the national stage application and to cancel the 218 patent, assigned to SCR Pharmatop. The PTO declined to consider Exela’s petition, stating that no law or regulation authorizes non-party challenge to a PTO ruling to accept a tardy filing. Exela then brought suit under the Administrative Procedure Act, arguing that the PTO’s action was ultra vires and that Exela’s petition should have been considered and favorably decided. The district court, on reconsideration and in view of new Fourth Circuit precedent, dismissed Exela’s complaint for failing to meet the statute of limitations for claims filed against the United States, including APA claims. The Federal Circuit affirmed the dismissal, on the ground that PTO revival rulings are not subject to third party collateral challenge, thereby precluding review regardless of whether Exela’s claims were time-barred.
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.